Log in

NASDAQ:ETTX - Entasis Therapeutics Stock Price, Forecast & News

-0.01 (-0.19 %)
(As of 02/17/2020 01:46 AM ET)
Today's Range
Now: $5.24
50-Day Range
MA: $4.99
52-Week Range
Now: $5.24
Volume5,032 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
Entasis Therapeutics Holdings, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the discovery and development of novel antibacterial products. The firm develops a portfolio of innovative cures for serious drug-resistant bacterial infections. Its anti-infective discovery platform has produced a pipeline of differentiated programs, which is bacterial infections, including ETX2514SUL (targeting Acinetobacter baumannii infections), ETX0282CPDP (targeting Enterobacteriaceae infections), Non-Beta-lactam PBP inhibitor, and Zoliflodacin. Entasis Therapeutics Holdings was founded in March 2018 and is headquartered in Waltham, MA.

Industry, Sector and Symbol

Industry N/A
Current SymbolNASDAQ:ETTX



Sales & Book Value

Annual SalesN/A



Next Earnings Date4/3/2020 (Estimated)
OptionableNot Optionable

Receive ETTX News and Ratings via Email

Sign-up to receive the latest news and ratings for ETTX and its competitors with MarketBeat's FREE daily newsletter.

Entasis Therapeutics (NASDAQ:ETTX) Frequently Asked Questions

What is Entasis Therapeutics' stock symbol?

Entasis Therapeutics trades on the NASDAQ under the ticker symbol "ETTX."

How were Entasis Therapeutics' earnings last quarter?

Entasis Therapeutics Holdings Inc (NASDAQ:ETTX) announced its quarterly earnings data on Thursday, November, 14th. The company reported ($0.27) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.87) by $0.60. The firm earned $7 million during the quarter. View Entasis Therapeutics' Earnings History.

When is Entasis Therapeutics' next earnings date?

Entasis Therapeutics is scheduled to release their next quarterly earnings announcement on Friday, April 3rd 2020. View Earnings Estimates for Entasis Therapeutics.

What price target have analysts set for ETTX?

2 brokerages have issued 1-year price objectives for Entasis Therapeutics' stock. Their forecasts range from $18.00 to $19.00. On average, they anticipate Entasis Therapeutics' share price to reach $18.50 in the next twelve months. This suggests a possible upside of 253.1% from the stock's current price. View Analyst Price Targets for Entasis Therapeutics.

What is the consensus analysts' recommendation for Entasis Therapeutics?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Entasis Therapeutics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Entasis Therapeutics.

Has Entasis Therapeutics been receiving favorable news coverage?

Headlines about ETTX stock have trended somewhat positive on Monday, according to InfoTrie. The research firm identifies positive and negative media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Entasis Therapeutics earned a daily sentiment score of 2.0 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for Entasis Therapeutics.

Are investors shorting Entasis Therapeutics?

Entasis Therapeutics saw a decrease in short interest in the month of January. As of January 31st, there was short interest totalling 37,400 shares, a decrease of 13.8% from the January 15th total of 43,400 shares. Based on an average daily trading volume, of 10,600 shares, the short-interest ratio is currently 3.5 days. Approximately 1.4% of the shares of the stock are short sold. View Entasis Therapeutics' Current Options Chain.

What other stocks do shareholders of Entasis Therapeutics own?

Who are Entasis Therapeutics' key executives?

Entasis Therapeutics' management team includes the folowing people:
  • Manoussos Perros, President, Chief Executive Officer & Director
  • Mike Gutch, Chief Financial Officer & Chief Business Officer
  • Ruben Tommasi, Chief Scientific Officer
  • Robin Isaacs, Chief Medical Officer
  • John Mueller, Chief Development Officer

When did Entasis Therapeutics IPO?

(ETTX) raised $75 million in an initial public offering (IPO) on Wednesday, September 26th 2018. The company issued 4,400,000 shares at a price of $16.00-$18.00 per share. Credit Suisse and BMO Capital Markets served as the underwriters for the IPO and SunTrust Robinson Humphrey and Wedbush PacGrow were co-managers.

Who are Entasis Therapeutics' major shareholders?

Entasis Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Eventide Asset Management LLC (6.62%) and Renaissance Technologies LLC (0.19%). Company insiders that own Entasis Therapeutics stock include Group Holdings (Sbs) Advis Tpg, Holdings A/S Novo and Nicholas Galakatos. View Institutional Ownership Trends for Entasis Therapeutics.

Which major investors are buying Entasis Therapeutics stock?

ETTX stock was acquired by a variety of institutional investors in the last quarter, including Eventide Asset Management LLC and Renaissance Technologies LLC. Company insiders that have bought Entasis Therapeutics stock in the last two years include Group Holdings (Sbs) Advis Tpg, Holdings A/S Novo and Nicholas Galakatos. View Insider Buying and Selling for Entasis Therapeutics.

How do I buy shares of Entasis Therapeutics?

Shares of ETTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Entasis Therapeutics' stock price today?

One share of ETTX stock can currently be purchased for approximately $5.24.

MarketBeat Community Rating for Entasis Therapeutics (NASDAQ ETTX)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  72 (Vote Outperform)
Underperform Votes:  73 (Vote Underperform)
Total Votes:  145
MarketBeat's community ratings are surveys of what our community members think about Entasis Therapeutics and other stocks. Vote "Outperform" if you believe ETTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ETTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/17/2020 by MarketBeat.com Staff

Featured Article: What are economic reports?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel